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Abstract
Alport syndrome results from mutations in the COL4A5 (X-linked) or COL4A3/COL4A4
(recessive) genes. This study examined 754 previously- unpublished variants in these
genes from individuals referred for genetic testing in 12 accredited diagnostic laboratories
worldwide, in addition to all published COL4A5, COL4A3 and COL4A4 variants in the LOVD
databases. It also determined genotype-phenotype correlations for variants where clinical
data were available. Individuals were referred for genetic testing where Alport syndrome
was suspected clinically or on biopsy (renal failure, hearing loss, retinopathy, lamellated glo-
merular basement membrane), variant pathogenicity was assessed using currently-
accepted criteria, and variants were examined for gene location, and age at renal failure
onset. Results were compared using Fisher’s exact test (DNA Stata). Altogether 754 new
DNA variants were identified, an increase of 25%, predominantly in people of European
background. Of the 1168 COL4A5 variants, 504 (43%) were missense mutations, 273
(23%) splicing variants, 73 (6%) nonsense mutations, 169 (14%) short deletions and 76
(7%) complex or large deletions. Only 135 of the 432 Gly residues in the collagenous
sequence were substituted (31%), which means that fewer than 10% of all possible variants
have been identified. Both missense and nonsense mutations in COL4A5 were not ran-
domly distributed but more common at the 70 CpG sequences (p<10−41 and p<0.001
respectively). Gly>Ala substitutions were underrepresented in all three genes (p< 0.0001)
probably because of an association with a milder phenotype. The average age at end-stage
renal failure was the same for all mutations in COL4A5 (24.4 ±7.8 years), COL4A3 (23.3 ±
9.3) and COL4A4 (25.4 ± 10.3) (COL4A5 and COL4A3, p = 0.45; COL4A5 and COL4A4, p =
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0.55; COL4A3 and COL4A4, p = 0.41). For COL4A5, renal failure occurred sooner with non-
missense than missense variants (p<0.01). For the COL4A3 and COL4A4 genes, age at
renal failure occurred sooner with two non-missense variants (p = 0.08, and p = 0.01
respectively). Thus DNA variant characteristics that predict age at renal failure appeared to
be the same for all three Alport genes. Founder mutations (with the pathogenic variant in at
least 5 apparently- unrelated individuals) were not necessarily associated with a milder phe-
notype. This study illustrates the benefits when routine diagnostic laboratories share and
analyse their data.
Introduction
Alport syndrome is the commonest cause of inherited renal failure after polycystic kidney dis-
ease [1]. It affects at least one in 10,000 individuals and is characterised by progressive kidney
failure, hearing loss, and ocular abnormalities [2]. Inheritance is X-linked with COL4A5muta-
tions [3] in 85% of cases and autosomal recessive with COL4A3 or COL4A4mutations in most
of the others [4,5]. Individuals with heterozygous COL4A3 or COL4A4mutations usually have
Thin basement membrane nephropathy with normal renal function [6,7,8] but some develop
renal impairment [9].
The clinical features in Alport syndrome are explained because the COL4A5 and COL4A3/
COL4A4 genes code for the collagen IV α5 chain, α3 and α4 chains which form a heterotrimer
in the basement membranes of the glomerulus, cochlea and eye [10] (Table 1). Each collagen
IV chain has non-collagenous amino and carboxy termini, and an intermediate collagenous
domain with Gly-X-Y, with multiple short non-collagenous interruptions [10]. Glycine is
found at each third residue in the collagen sequence and is critical for triple helix formation.
The ‘Expert guidelines on the diagnosis and management of Alport syndrome’ [2] recom-
mend that all individuals with likely Alport syndrome should undergo genetic testing, to con-
firm the diagnosis and mode of inheritance, and predict the age at renal failure. The Guidelines
also recommend cases of suspected Thin basement membrane nephropathy undergo genetic
testing when it is important to exclude X-linked Alport syndrome [2].
Mutations in the COL4A5, COL4A3 and COL4A4 genes are mainly nonsense or missense.
Genotype-phenotype correlations have only been characterised for X-linked disease [11,12,13].
Nonsense mutations are typically associated with early onset renal failure (before 30), lentico-
nus and central retinopathy. Deletions and insertions often cause a frameshift, and down-
stream nonsense variant. Many missense mutations result in a milder phenotype with later
onset renal failure without ocular features [11,12,13,14].
The commonest method used currently for mutation detection is whole exome sequencing
(WES). The widespread adoption of WES together with the Exome Aggregation Consortium
(ExAc collaboration, http://exac.broadinstitute.org/, the ‘1000 genomes’, http://1000genomes.
org/ and Hapmap, https://hapmap.ncbi.nlm.nih.gov/, projects), have greatly increased the
number of reported pathogenic and normal DNA variants [15].
Collecting all pathogenic and normal variants for each disease-related gene in a publicly-
accessible variant database avoids the duplication involved in assessing pathogenicity, and
improves the speed and accuracy of testing while limiting cost.
The present study has reviewed known variants in the Alport genes, including 754 recently-
submitted from members of the Alport mutation database Consortium to the publicly-accessi-
ble LOVD databases, with the aims of further characterising DNA variants, and genotype-phe-
notype correlations. The LOVD databases continue to be updated.
Alport Syndrome: Further genotype-phenotype correlations
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Methods
Assembly of the variants
DNA variants were extracted from the literature, from other databases (eg ARUP) or from pre-
viously-unpublished deidentified submissions direct to the LOVD COL4A5, COL4A3 and
COL4A4 database from contributing members of the International Alport Mutation Database
Consortium in the UK and Europe, Korea, the US and Australia. Genetic testing from laborato-
ries run by Consortium members was performed after written informed consent had been
obtained by the treating clinicians. Submission of variants to the databases was undertaken
with IRB approval where this was required (Northern Health HREC, IRB of Seoul National
University, CEIC Fundacio Puigvert, Veltishev Pediatric Clinical Research Institute).
In general, individuals had been referred for genetic testing where Alport syndrome was sus-
pected clinically or on renal biopsy (renal failure, hearing loss, retinopathy, lamellated glomer-
ular basement membrane). Clinical data (age, gender, diagnosis and age at onset of renal
failure, and, where known, hearing loss and ocular abnormalities) were obtained in a manner
conforming with local IRB ethical guidelines according to the Declaration of Helsinki. The test-
ing laboratory deidentified information before submission to the databases.
Variants had been collected by individual laboratories over a ten year period and mutation
detection methods varied during this time. All laboratories had used Sanger sequencing at
some stage, few had used MLPA, but recently most had used whole exome sequencing. Most
diagnostic laboratories confirmed any variant found with WES using Sanger sequencing. All
laboratories were accredited by their national board but there was no uniformity in how they
confirmed variant pathogenicity. This was most often with consulting the LOVD, and recently,
the ExAc databases, and sometimes using an online tool such as Alamut.
Variants were described according to the reference transcripts of COL4A5 (the longer form
found in the kidney, LRG_232t2, NM_033380.2), COL4A3 (LRG_230t1, NM_000091.4) and
COL4A4 (LRG_231t1, NM_000092.4), and the nomenclature guidelines of the Human
Genome Variation Society (HGVS) [16]. Variant descriptions were confirmed with the Muta-
lyzer programme (http://mutalyzer.nl/) [17]. Pathogenicity assessments were as published or
as provided by the submitting laboratory. In general these were based on the HGVS definitions
[18]. Variants were not checked independently with any algorithms such as the Human Splic-
ing Finder because their efficacy and accuracy is not confirmed in the genes of interest. Our
Table 1. Characteristics of COL4A5,COL4A3 andCOL4A4 genes and the corresponding proteins.
COL4A51 COL4A32 COL4A4
Gene name NP_033380.2 NP_000091.4 NP_000092.4
Chromosomal location Xq22 2q35-37 2q35-37
Family *COL4A1-like *COL4A1-like *COL4A2-like
Number of exons 53 52 48
Size 257,623 bp 150,228 bp 159,344 bp
Total number of amino acids in mature protein 1665 1642 1652
Signal peptide 26 28 38
Amino terminus 15 14 23
Collagenous domain (residues) 1301 1268 1284
Number of non-collagenous interrruptions 22 23 26
Carboxy terminus (residues) 229 232 231
*COL4A–like or COL4A2-like genes represent families that have arisen from common progenitors, COL4A1 or COL4A2, and thus have structural similarities
doi:10.1371/journal.pone.0161802.t001
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definition for splicing mutations included the 10 intronic nucleotides immediately adjacent to
the exon-intron boundaries. Deep intronic variants were only included where the submitting
laboratory believed them to be disease-causing.
Variants, demographic and clinical data were added to the LOVD databases that included
all published COL4A5, COL4A3 and COL4A4 variants. Disease-associated variants already
recorded in the database but from apparently unrelated families were included to identify the
prevalence of Alport syndrome and any common or founder mutations. Mode of inheritance,
gender and clinical features were noted where available.
Analysis of the LOVD COL4A5, COL4A3 and COL4A4 databases
Different variant types (deletions, insertions, short deletions, arbitrarily chosen as< than 26
bp, and splicing variants) direct or indirect nonsense mutations, missense variants (resulting in
Gly or non-Gly substitutions, pathogenic or not, and synonymous changes) were counted.
Each variant was included once only in the analysis.
Large deletions were mapped against the collagen sequence. Missense variants corrected for
exon size were compared between exons to determine any increase in variants or gaps.
In addition, COL4A5missense mutations were tested for a preferential occurrence in CpG-
associated codons [19] (especially involving the first G of Gly) using an in-house Python script
(www.python.org). CpG sites have an increased tendency for methylcytosine to spontaneously
deaminate to thymine. CG>TG and the complementary changes have a 10 times higher muta-
tion rate than normal.
The prevalence of Gly substitutions with each of 8 other amino acids or a stop codon was
compared with the expected distribution determined from collagen codon preferences [20].
Age at onset of renal failure
The nature of mutations was correlated with early and late onset renal failure, using the criteria
already identified for COL4A5 ‘severe’ variants (copy number variants, frameshifts, nonsense
and splice site mutations). Only one age was used for the variant in each family, and for
COL4A5 variants, the ages at renal failure in males and females were studied separately. Where
several members of the same family or unrelated individuals with the same mutation were
described, the youngest age of onset of renal failure was recorded. For COL4A3 and COL4A4,
the age at end-stage renal failure in males and females were combined, and the number of
severe variants recorded as none, one or two.
Statistical analysis
Results were expressed as mean and SD, and results compared using Fisher’s exact test (DNA
Stata). A p value of less than 0.05 was considered significant, and a p values less than 0.10, a
trend.
Results
Twelve laboratories involved worldwide in mutation testing for Alport syndrome collaborated
to submit 754 novel variants (504 COL4A5, 133 COL4A3, 117 COL4A4 variants) to the LOVD
databases. These contributions increased the total number of variants in the databases by 25%
(754/2959), to 1168 unique variants for COL4A5 (1951 total), 266 for COL4A3 (518 total) and
268 for COL4A4 (490 total) (Table 2). Most variants were pathogenic, or of unknown signifi-
cance, from individuals with Alport syndrome or Thin basement membrane nephropathy.
Alport Syndrome: Further genotype-phenotype correlations
PLOS ONE | DOI:10.1371/journal.pone.0161802 September 14, 2016 4 / 13
Most were from Europeans with COL4A5 variants, or were from Chinese (72 pathogenic, 12
normal), African (10, 8 normal), Hispanic (7 pathogenic) or Indian (2 normal) people.
DNA variants in COL4A5
The 1168 COL4A5 unique variants included 76 complex mutations or deletions of more than
26 nucleotides (7%), 55 insertions (5%), 13 duplications (1%), 169 short deletions (with fewer
than 26 nucleotides, 14%), and 16 indels (1%), 73 nonsense mutations (6%), 504 missense vari-
ants (43%) and 273 (23%) splicing variants (Table 2). Uncommonly two pathogenic variants
were found in the same individual (11/1168, 1%).
Large deletions/indels/rearrangements. There were 25 large deletions. Seven originated
in COL4A6 and terminated in exon 1 or the nearby intron of COL4A5. Eight large deletions
originated in exons 1–4. Only 9 deletions (fewer than half) had their origins after exon 4, and
six at exons 37 to 41.
Direct nonsense mutations. There were 73 (6%) direct nonsense mutations but the inser-
tions/deletions and duplications that result in a frameshift meant that there were potentially
402 variants producing a downstream nonsense change (34%). In addition, 17 direct stop
codons resulted from Gly substitutions (4%) which matched the expected prevalence (4%)
(Table 3).
Missense mutations. There were 504 missense variants (43%) of which 391 (33%) were
Gly substitutions, and 113 (10%) non-Gly substitutions. Thus Gly in COL4A5 was substituted
three times more often than other amino acids. Glycine can be substituted nine ways (Table 3),
and the substitutions with each residue occurred as often as expected except for Ala which was
underrepresented (4% compared with 13% expected). Ala is the least destabilising amino acid,
and results in a milder clinical phenotype, which may have been overlooked clinically
(p<0.0001)[20].
Table 2. Frequency of variants inCOL4A5,COL4A3 andCOL4A4 genes in LOVD databases.
COL4A5 LOVD COL4A3 LOVD COL4A4 LOVD
Total number of variants 1168 unique (1951 total) 266 unique (518 total) 268 unique (490 total)
Rearrangements or deletions, copy number variants 76 (7%) 0 3 (1%)
Duplications 13 (1%) 3 (1%) 4 (1%)
Insertions 55 (5%) 8 (3%) 8 (3%)
Deletions (1-26bp) 169 (14%) 31 (12%) 32 (12%)
Indels (with both insertions and deletions) 16 (1%) 3 (1%) 2 (1%)
Splicing variants 273 (152+ and 121-)* (23%) 25 (15+ and 10-)* (9%) 52 (25+ and 27-)* (19%)
Nonsense codons (direct) 73 (6%) 13 (5%) 13 (5%)
Total potential nonsense mutations (direct and downstream) 329 + 73 = 402 (34%) 45 + 13 = 47 (18%) 13 + 49 = 62 (23%)
Missense substitutions 504 (43%) 136 (51%) 107 (40%)
•Gly 391 (33%) 66 (25%) 46 (17%)
• Non-Gly 113 (10%) 70 (26%) 61 (23%)
Non-pathogenic changes 24 78 65
• Synonymous 11 44 28
• Non-Gly missense 7 28 14
• Deep intronic 6 6 23
* For splicing variants, + indicates that the variant is located within the intron immediately adjacent to the 3’ end of the exon; and—indicates that the exon is
within the intron immediately adjacent to the 5’ end of the exon.
doi:10.1371/journal.pone.0161802.t002
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Of the 113 non-Gly substitutions, the most common replacements were of Arg, Asp, Glu,
Ser (26, 9.5%), Val (10, 4%) or Ala (7, 2.6%), to Gly.
Only 135 of the 432 Gly in the collagenous sequence were substituted (31%). This was com-
parable with COL1A1 where fewer than 10% of all variants were calculated to be known
(Marini, 2007). Most substitutions were with one amino acid only.
Missense variants were not distributed evenly throughout the COL4A5 gene when exon size
was taken into account (Fig 1). There were fewer mutations in exons 47 and 48, which sug-
gested a milder phenotype or an ascertainment bias. It was unlikely that the fewer mutations
were due to an embryonic lethal phenotype because the collagen IV α3α4α5 network is mainly
expressed after infancy. However exons 47 and 48 correspond to the collagen IV α5 chain
before the carboxy terminus, where there is a ‘gap’ for entry of the cleavage enzymes, and the
major epithelial binding site on the parallel IV alpha3 chain [21]. Mutations were also under-
represented in exons 42 and 43 probably because these exons are small and not routinely
sequenced.
CpG site mutations. There were 70 CpG sites among the 5076 nucleotide positions in
COL4A5. Of all the mutations causing Alport syndrome, 89 were present at CpG sites which
was more often than by chance (p less than10- 41 by Fisher’s exact test). Nonsense mutations
were also observed more often at CpG sites. Of the 89 mutations at 70 CpG sites, 27 were non-
sense changes at 5 sites (p less than 0.001 by Fisher’s exact test).
Gly substitutions within the collagenous domains were also overrepresented in COL4A5
mutations. Of the 491 missense mutations affecting the 1347 amino acid positions in collagen
IV α5 chain, 435 (89%) were substitutions of one of the 449 collagenous domain Gly residues
(p<0.001). Similarly, at the CpG sites, 46 missense mutations were observed at 43 CpG sites
within the collagenous domains, with 39 resulting in Gly substitutions at 12 Gly positions (p
less than 10−7 by Fisher’s exact test).
Splice site mutations. There were 273 splicing variants (23% of total number) with a vari-
ant within 10 nucleotides of the intron-exon boundary that was possibly pathogenic. At least
one variant was identified for each intron, and there were 152 + (at the 3’ end of the exon) and
121 –(at the 5’ end of the exon) splice variants.
Founder mutations. Two hundred and sixty-five pathogenic variants (23%) were
recorded more than once, but only 12 reported at least five times in apparently unrelated fami-
lies (Table 4). Three were biochemically ‘severe’ mutations being a duplication or nonsense
variant. A further three were Gly substitutions. Six resulted in renal failure at less than 30 years
of age, and five in a milder phenotype with later onset renal failure.
Table 3. Observed versus expected likelihood of Glycine substitutions in the COL4A5,COL4A3 andCOL4A4 genes in Alport syndrome and Thin
basement membrane nephropathy. Observed number from the LOVD databases; expected number derived from data for collagen I [20].
Ala Ser Cys Arg Val Glu Asp Trp Stop
Expected (based on residue frequency and
collagen coding preferences)
13% 18% 6% 26% 10% 14% 14% 1% 4%
COL4A5 observed (n = 391) 15 (4%) (p less than
0.0001)
45 (11%)
(p = 0.02)
19
(5%)
86
(22%)
64
(16%)
56
(14%)
68
(17%)
3
(1%)
17
(4%)
COL4A3 observed (n = 66) 0 (0%) 8 (12%) 6 (9%) 23
(35%)
6 (9%) 13
(20%)
8 (12%) 1
(1%)
1 (1%)
COL4A4 observed (n = 46) 1 (2%) (p = 0.06) 7 (15%) 3 (7%) 15
(33%)
4 (9%) 11
(24%)
3 (7%) 1
(2%)
1 (2%)
p- not signiﬁcant for all other comparisons
doi:10.1371/journal.pone.0161802.t003
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Some of these mutations will have arisen from independent events and others from a single
individual, but the distinction can only be made with haplotype analysis. These mutations
allow us to examine the consistency of age of onset of renal failure and the effect of modifying
genes. More founder mutations are likely but laboratories may not have not reported them
because of their ‘lack of novelty’.
Genotype-phenotype correlation. Clinical data were most complete for age at end-stage
renal failure. Formal hearing and ophthalmic examinations were rarely reported to the testing
laboratory.
Reported mutations were associated more often with a severe phenotype. The age at onset
of renal failure was available for 237 COL4A5mutations (12%) and the mean age was 24.3
years (Table 5). More mutations (162, 68%) were associated with end-stage renal failure before
the age of 30 years, than later (75, 32%).
A severe mutation (rearrangement, large deletion, insertion/deletion, or nonsense change)
was associated with a younger average age at onset of renal failure of 22.5 ± 7.0 years (n = 131)
than in those without a severe mutation (26.7 ± 8.1 years, n = 106, p less than 0.01).
A direct nonsense mutation, that is where a codon was replaced by a stop signal, was associ-
ated with a younger average age at onset of renal failure of 21.4 ± 6.4 years than with other
mutations types (p = 0.03).
Fig 1. Distribution of missense variants in theCOL4A5 gene in each exon corrected for exon size and demonstrating a non-uniform distribution.
doi:10.1371/journal.pone.0161802.g001
Alport Syndrome: Further genotype-phenotype correlations
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There was no difference in the age at onset of renal failure in individuals with Gly substitu-
tions with Arg, Glu or Asp compared with other amino acids, nor with non-Gly substitutions
(p all greater than 0.05).
COL4A5mutations were reported in 68 females. Nine of the 23 (39%) who developed renal
failure had a direct or indirect nonsense mutation or rearrangement or insertion/deletion, in
contrast to 9 of the 45 without renal failure (20%, p = 0.14).
DNA variants in COL4A3 and COL4A4
Many fewer DNA variants have been described for the COL4A3 and COL4A4 genes, presum-
ably because autosomal recessive Alport syndrome is less common, and genetic testing is per-
formed infrequently for Thin basement membrane nephropathy.
DNA variants in the LOVD databases affected the COL4A3 and COL4A4 genes equally fre-
quently (Table 2). The COL4A3 database had 266 unique variants, and COL4A4 had 268. Com-
pound heterozygous variants were more common than homozygous variants for both COL4A3
and COL4A4 (69% and 59% respectively) suggesting lesser consanguinity.
Table 4. Common Founder mutations in theCOL4A5,COL4A3 andCOL4A4 genes.
Variant Number of reports/
families
Ethnicity Clinical features, Age at onset of renal
failure
Reference
COL4A5 Tandem duplication of 35
exons
>160 individuals French Polynesian ESRF at 31 years, lenticonus [28]
p.Gly325Arg Reported 9 times France, European ESRF at 22–76 years, hearing loss [29]
p.Arg373* Reported 6 times Italian ESRF at 15 years, hearing loss [30]
p.Gly624Asp Reported at least 5 times European ESRF late [31,32]
p.Gly869Arg Reported 12 times Italian ESRF at 10 years [30]
p.Ser916Gly Reported 5 times US Not available [33]
p.Gly953Val Reported 6 times France ESRF at 15 years, hearing loss [34]
p.Gly1030Ser Reported 5 times N European, US ESRF at 37 years, hearing loss [31]
p.Arg1569Gln Reported 7 times US, France ESRF at 29 years, hearing loss [34,35]
p.Leu1655Arg Reported in 9 families Western US ESRF at 40 years, hearing loss [36]
p.Arg1683Gln Reported 5 times Ashkanazi-American ESRF 40–62 years [37]
p. Arg1683* Reported 6 times British ESRF at 27 years, hearing loss [38]
COL4A3 c.40-63del One in 183 Ashkenazi Askhkenazi-American ARAS [39]
p.Gly43Arg Reported 5 times European, US TBMN, AR AS [40]
p.Glu162Gly Reported 8 times European, US TBMN, AR AS [40]
p.Gly695Arg Reported 5 times British Haematuria, TBMN [41]
p.Gly871Cys 6 families Cypriot Haematuria, TBMN and FSGS [42,43]
p.Gly1334Glu 4 families Cypriot TBMN, FSGS [42,43]
p. Gln1495Arg Reported 5 times European, British,
Cypriot
AR AS, TBMN [44]
p. 13_22 del LPLLLVLL 1:183 of Ashkanazi American Ashkenazi AR AS [39]
COL4A4 p.Gly545Ala Reported 11 times Turkish, German TBMN, AR AS [45]
c.2384-5T>C Reported 6 times Italian TBMN [44]
p.A880Hisfs69* Reported 5 times Australian AR AS [46]
p.Gly960Arg Reported 6 times Spanish TBMN [47]
p.Ser969* Reported 14 times British AR AS with early onset ESRF; TBMN [48]
*stop codon; ESRF–end-stage renal failure, FSGS–focal segmental glomerulosclerosis, AR AS–autosomal recessive Alport syndrome, TBMN–thin
basement membrane nephropathy
doi:10.1371/journal.pone.0161802.t004
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Large deletions/indels/rearrangements. The proportions of duplications, insertions,
short deletions and other indels were similar to those found in COL4A5.
Missense. Glycine substitutions were relatively less abundant than for COL4A5 (Table 2).
This was unexpected since they are the most common change in X-linked Alport syndrome
and other collagen diseases such as osteogenesis imperfecta [20]. The explanation may be that
milder disease with heterozygous Gly substitutions was overlooked. Gly to Ala or Ser substitu-
tions were again underrepresented for the COL4A3 and COL4A4 genes.
Too few missense variants were found to determine any mutational hot spots. Non-Gly sub-
stitutions were more common than in COL4A5, but their pathogenic significance was often not
clear.
Nonsense. The % of direct nonsense mutations was similar to COL4A5 but the total % (of
direct and potential indirect nonsense mutations) was fewer because fewer large insertions/
deletions were reported.
Splicing. Very few potential splicing mutations were identified within the first 10 nucleo-
tides of the intron-exon boundaries.
Founder mutations. Founder mutations were reported in both COL4A3 and COL4A4 in
autosomal recessive Alport syndrome and Thin basement membrane nephropathy (Table 5).
For example, the S969X variant in COL4A4 was the commonest variant in British populations,
and other variants were reported from Cyprus.
Genotype-phenotype correlations. Clinical features were compared between individuals
with autosomal recessive Alport syndrome caused by COL4A3 or COL4A4 pathogenic muta-
tions and those with X-linked Alport syndrome and COL4A5mutations. The age at onset of
renal failure was known for some homozygous or compound heterozygous COL4A3 (n = 35)
and COL4A4 (n = 25) pathogenic mutations where both variants were known. Overall the
mean age at onset of end-stage renal failure was not different for individuals with COL4A3
(23.2 + 9.3, years, 95% CI 20.1 to 26.5) or COL4A4mutations (mean 25.4 ±10.3 years, 95% CI
21.3 to 29.6) compared with COL4A5mutations (24.4 ± 7.8 years, 95% CI 23.4 to 25.4,
n = 237) (Table 4).
Table 5. Age at end-stage renal failure and severity of mutations withCOL4A5,COL4A3 andCOL4A4 variants.
COL4A5 COL4A3 COL4A4
Total number with end-stage renal failure
and all causative mutations identiﬁed
237 75 48
Age at renal failure for all patients with
mutations in this gene (mean, SD, years)
24.4, 7.8 (23.4 to 25.4) (n = 237) (COL4A5 and
COL4A3, p = 0.45; COL4A5 and COL4A4,
p = 0.55)
23.3, 9.3 (20.1 to 26.5) (n = 35)
(COL4A3 and COL4A4,
p = 0.41).
25.4, 10.3 (21.3 to 29.6)
(n = 26)
End-stage renal failure at < 30 years 162 (68%)
Number of homozygous mutations N/A 16 (21%) 15 (31%)
Number of compound heterozygous
mutations
N/A 59 (79%) 33 (69%)
Age at onset of renal failure
No severe mutation (mean, SD, years) 26.7, 8.1 (n = 106) 24.0, 6.9 (n = 8) 26.6, 5.0 (n = 9)
One severe mutation (mean, SD, years) 22.5, 7.0 (n = 131) (one compared with none, p
less than 0.01)
20.8, 5.1 (n = 8) 25.5, 7.8 (n = 4)
Two severe mutations (mean, SD, years) Not applicable 17.6, 8.5 (n = 14) (two compared
with none, p = 0.08)
21.1, 3.6 (n = 10) (two
compared with none,
p = 0.01)
Direct nonsense mutation 21.4, 6.4 (16.9 to 25.9) (n = 12) 17.9, 5.5, (13.3 to 22.5) (n = 8)
‘Severe’mutations were large rearrangements, deletions, insertions or other changes resulting in a nonsense codon.
doi:10.1371/journal.pone.0161802.t005
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The age at onset of renal failure was also the same for homozygous and for compound het-
erozygous COL4A3 and COL4A4mutations (21.5 ± 7.2, 95%CI 17.2–25.9, n = 13; and
21.8 ± 7.0, 95% CI 19.8 to 23.7, n = 52).
Subjects with two severe mutations (direct or indirect nonsense mutations, insertions/dele-
tions) developed end-stage renal failure at a younger age than those with none (Table 4). Indi-
viduals with at least one direct nonsense COL4A3 or COL4A4mutation also developed renal
failure at a younger age than those with none. Thus, the age at onset of renal failure in autoso-
mal recessive Alport syndrome depended on mutation severity using the same criteria as for
COL4A5mutations [11,12]. However this study did not demonstrate any difference in the age
at end-stage renal failure due to Gly substitutions with Arg, Glu or Asp compared with other
substitutions for COL4A3 and COL4A4.
Twenty COL4A3 or COL4A4mutations were identified in the LOVD databases in individu-
als diagnosed clinically with autosomal dominant Alport syndrome. Seven only had developed
end-stage renal failure, at a mean age of 42 ± 15.1 years (range 20–60). The others either did
not have renal failure or the age at onset was not known.
Biallelic and digenic mutations
There are occasional reports of individuals with two COL4A5mutations [22,23], and others
with autosomal recessive Alport syndrome and mutations in both COL4A3 and COL4A4 with
a later age at onset of renal failure [15,24,25].
Discussion
This study confirmed that COL4A5, and COL4A3 and COL4A4mutations in Alport syndrome
all resulted in end-stage renal failure at the same age. Other studies have found that COL4A5
deletions, insertions, and nonsense variants, are associated with early onset renal failure
[11,12,13]. This study confirmed that two COL4A3 or COL4A4mutations resulted in earlier
onset renal failure than one or no severe mutations. Nonsense COL4A3 and COL4A4muta-
tions were also associated with a younger age at renal failure. Cohort studies indicate that hear-
ing loss is common with all mutation types, and that the same mutation types that cause early
onset renal failure in X-linked disease are associated with lenticonus and retinopathy [14].
The number of different published COL4A5 variants has increased from 176 in 1997 [26], to
520 by 2010 [27], and 1200 in 2015. Many more pathogenic variants have been reported for
COL4A5 than for COL4A3 and COL4A4. There was some bias in the types of mutations
reported here (deletions and insertions were more common for COL4A5) probably because of
the detection techniques.
The major challenge for the future is to encourage all diagnostic laboratories including
those that are commercially-based, to submit their variants to a database, together with accu-
rate pathogenicity assessments and as much clinical information as possible. The classification
of some so- called benign variants will be revised. We will understand better genotype-pheno-
type correlations for heterozygous COL4A3 and COL4A4mutations in Thin basement mem-
brane nephropathy, and any genetic distinctions from variants that cause autosomal dominant
Alport syndrome. In addition we will better understand the consequences of biallelic, triallelic
and digenic COL4mutations [25], and possibly why some heterozygous COL4mutations are
associated with proteinuria.
Increasingly the value of sharing variants and pathogenicity assessments is realised. Some
countries allow all variants identified in public laboratories to be shared in public databases
without specific assent, and IRBs internationally are finding that the public benefit of sharing
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outweighs any small adverse risk. Our study exemplifies the advantages of sharing variants in a
rare disease.
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